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Abstract
A consensus has yet to emerge whether deep brain stimulation (DBS) for treatment-refractory obsessive-compulsive disorder
(OCD) can be considered an established therapy. In 2014, the World Society for Stereotactic and Functional Neurosurgery
(WSSFN) published consensus guidelines stating that a therapy becomes established when “at least two blinded randomized
controlled clinical trials from two different groups of researchers are published, both reporting an acceptable risk-benefit
ratio, at least comparable with other existing therapies. The clinical trials should be on the same brain area for the same
psychiatric indication.” The authors have now compiled the available evidence to make a clear statement on whether DBS
for OCD is established therapy. Two blinded randomized controlled trials have been published, one with level I evidence
(Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score improved 37% during stimulation on), the other with level II
evidence (25% improvement). A clinical cohort study (N= 70) showed 40% Y-BOCS score improvement during DBS, and
a prospective international multi-center study 42% improvement (N= 30). The WSSFN states that electrical stimulation for
otherwise treatment refractory OCD using a multipolar electrode implanted in the ventral anterior capsule region (including
bed nucleus of stria terminalis and nucleus accumbens) remains investigational. It represents an emerging, but not yet
established therapy. A multidisciplinary team involving psychiatrists and neurosurgeons is a prerequisite for such therapy,
and the future of surgical treatment of psychiatric patients remains in the realm of the psychiatrist.
Introduction
Determining when research should be considered mature
enough to support the establishment of a therapy is ethically
complex, especially when considering deep brain stimula-
tion (DBS) for psychiatric disorders, an invasive procedure
that modulates brain function [1]. In this paper, we chart the
evolution of DBS for treatment refractory obsessive-
compulsive disorder (OCD) and present the consensus
view of the Task Force on Neurosurgery for Psychiatric
Disorders of the WSSFN on why this intervention can be
considered an emerging and not an established therapy yet.
History
The U.S. Food and Drug Administration (FDA) approved
DBS for treatment-refractory OCD as a humanitarian device
exemption (HDE H050003) in 2009. FDA-HDE approval
does not require that applicants demonstrate efficacy, but
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applicants do need to show that the intervention does not
pose unreasonable risks [2]. This FDA-HDE approval has
been criticized, as the evidence for safety and efficacy of
DBS in OCD at that time was limited [3].
Also in 2009, a Conformité Européenne (CE mark) was
obtained by Medtronic Inc. and reimbursement was
achieved in several, but not all, EU countries. However, CE
mark at the time of approval only referred to the safety of a
product for a particular use, i.e., DBS in the internal capsule
and its vicinities using a particular DBS electrode from a
particular provider. The CE mark states nothing about
efficacy, patient selection criteria, etc.
In 2014, the Neurosurgery Committee for Psychiatric
Disorders of the WSSFN published consensus guidelines
for the use of stereotactic neurosurgical interventions to
treat refractory psychiatric disorders [4]. The consensus
statement noted that, “In this delicate field of neurosurgery
for psychiatric disorders, it seems reasonable to state the
following requirement before the surgical intervention can
be stated as “approved therapy”. At least two blinded (if
feasible) randomized controlled clinical trials from two
different groups of researchers need to be published, both
reporting an acceptable risk-benefit ratio, at least compar-
able with other existing therapies. The clinical trials should
be on the same brain area for the same psychiatric
indication.”
Evidence
The Task Force on Neurosurgery for Psychiatric Disorders
of the WSSFN, which is the successor organization to the
Neurosurgery Committee for Psychiatric Disorders of the
WSSFN, now recognizes that two such blinded randomized
controlled trials have been published [5, 6]. Below is a brief
summary of the results of these two studies, both using DBS
of the ventral anterior capsule region for the treatment of
refractory OCD.
Denys et al. reported on their patients with stimulation on
(open label phase) for 8 months before randomization [5].
Nine out of 16 patients were responders, with a mean
decrease of 46% in Yale-Brown Obsessive Compulsive
Scale (Y-BOCS) score during the initial open-label phase.
Following these 8 months, there was a 2-week cross-over
phase, during which the Y-BOCS dropped 25% during
active DBS versus sham, using a double-blind, sham-
controlled design. While encouraging, this decrease in Y-
BOCS score did not achieve a response rate generally
considered to be a minimum of a 35% decrease in Y-BOCS
score [7]. In summary, a significant albeit less than optimal
effect was observed in the active stimulation phase (25% vs.
the required 35%).
In a different study, Luyten et al. reported in 17 patients a
response rate of 53% and a significant improvement
(median: 37%) in Y-BOCS scores when comparing the
blinded ON phase with the blinded OFF phase during a
randomized cross-over trial [6]. During the open label
phase, 67% of the patients were responders and the median
decrease in Y-BOCS score was 58%.
Of note, these two studies targeted slightly different loci
in the brain. Denys et al. targeted the nucleus accumbens
[5]. However, as documented in subsequent publications,
the active electrode contacts were located dorsal to this
target, in the ventral anterior limb of the internal capsule [8].
Luyten et al. targeted the bed nucleus of the stria terminalis
[6]. These structures are in very close proximity, and in both
studies electrical contacts of leads of various designs were
also located in the anterior limb of the internal capsule. Both
studies reported acceptable safety and efficacy.
What level of evidence can we assert for the efficacy of
this intervention in refractory OCD? Level I evidence
implies, in practice, that “clinicians should follow the strong
recommendation unless a clear and compelling rationale for
an alternative approach is present” [9–11]. According to the
Canadian Task Force on the Periodic Health Examination’s
Levels of Evidence, one needs at least one randomized
controlled trial (RCT) with proper randomization to obtain
level I evidence [9]. Concerning the results of the Denys
et al. study, in our opinion only the Luyten et al. study
fulfills the Canadian Task Force requirement [5, 6]. Sackett
et al. categorize outcomes as follows: level of evidence I
requires RCTs with enough power and sample sizes large
enough to achieve significance; level II signifies small
RCTs with unclear results [12]. Taken together, we consider
that Denys et al.’s study qualified for level II and Luyten
et al.’s study qualified for level I, even though it included a
small number of participants [5, 6]. We make this assertion
because neuromodulation trials for OCD do not, and will
never, command large numbers of participants and, for that
reason, large RCTs (as, for example, in drug trials) are not
feasible. While only a very small number of patients meet
the inclusion and exclusion criteria for this kind of surgical
intervention, a large effect was obtained by DBS in Luyten
et al. paper consistent with level I evidence for efficacy of
the therapy [6]. Moreover, the paper of Luyten et al. is
considered as class I evidence for DBS in OCD according to
Bari et al. [6, 13]. None of the authors of the paper of
Luyten et al. co-authored the paper of Bari et al. [6, 13].
Recommending a GRADE level according to the GRADE
Practice Recommendations would require an extensive
effort and has not yet been achieved [14].
Furthermore, two non-randomized studies—the largest in
this field—substantiate the results, obtained in the Luyten
et al. paper [6, 15, 16]. Target was anterior internal capsular
region, including bed nucleus of stria terminalis and/or
nucleus accumbens. In a clinical cohort study of 70 patients,
a 40% reduction of mean Y-BOCS scores was observed
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after 12 months of open label DBS, with 36 of the 70
patients being categorized as responders (52%), 12 patients
as partial responders (17%), and 22 patients as non-
responders (31%) [15]. Adverse events included transient
symptoms of hypomania, agitation, impulsivity, and sleep
disorders.
In a further open prospective international multi-center
study, a mean Y-BOCS reduction of 42% at 12 months (N
= 30) was obtained and the responder rate was 60% [16].
Most adverse events were mild or moderate, transient and
related to programming/stimulation and tended to resolve
by adjustment of stimulation parameters.
In summary, there are convincing beneficial effects of
DBS on OCD symptoms in carefully selected patients who
are refractory to expert psychological therapy (typically
cognitive behavioral therapy) and rigorous pharmacological
treatment.
This emerging consensus can be corroborated based on
discussions at five recent scientific meetings (Congress of
the WSSFN 2017, Berlin; Joint Meeting of the Neuro-
surgical Societies of Belgium and The Netherlands, Den
Bosch, 2017; Congress of the Japanese Neurosurgical
Society, October 2017; Neuromodulation, the rising trend in
treating nervous system disorders, Samsun, Turkey, Octo-
ber 2017; Asia-Pacific Centre for Neuromodulation—DBS
symposium, Brisbane, November 2017). Compared to
ablative lesional surgery (bilateral anterior capsulotomy,
bilateral cingulotomy, subcaudate tractotomy or limbic
leucotomy), which has been performed and documented for
decades, DBS offers the advantage of being partially
reversible, at least in the short-term [17]. However, DBS for
OCD remains an expensive treatment with a heavy clinical
service work-load in terms of programming and life-long
follow up, and it is not without risk [18, 19].
Role of the psychiatrist
Notwithstanding the accumulating evidence of the effec-
tiveness of DBS for OCD, and despite the need for alter-
native treatments for patients who do not respond to
available psychological and pharmacological therapies,
even when expertly delivered, only a few psychiatrists seem
to take the initiative to consider neurosurgical options. The
statement of Laitinen from 1977 remains valid: In a pub-
lication titled “Ethical aspects of psychiatric surgery” he
wrote: “The basic problem of psychosurgery is psychiatric,
therefore the initiative in considering surgical treatment
must be taken by the psychiatrist. As soon as the psychia-
trist is sure that conservative treatment by every available
method cannot cure the patient, the psychiatrist should
consult the neurosurgeon. Psychosurgery will remain
experimental for years. Therefore, its use should be con-
centrated and restricted to psychosurgical research units
having strong and intimate affiliation with scientists from
many disciplines” [20]. That statement was made during the
stereotactic lesional era, and remains valid today in the
DBS era.
The Task Force on Neurosurgery for Psychiatric Dis-
orders of the WSSFN reaches out to psychiatrists to
improve communication between psychiatrists and neuro-
surgeons to carefully evaluate when it may be in the best
interest of a patient to consider neurosurgery and to
implement an ethical scientific program for surgical treat-
ment of refractory OCD patients.
Conclusion
The Task Force on Neurosurgery for Psychiatric Disorders
of the WSSFN accepts that electrical stimulation for
otherwise treatment refractory obsessive-compulsive dis-
order using a multipolar electrode implanted in the region
of the bed nucleus of the stria terminalis and/or anterior
limb of the internal capsule represents an emerging
therapy.
This is based on the following data: one peer-reviewed
scientific paper with level 1 evidence for electrical stimu-
lation of this target region for treatment refractory patients
with OCD [6], one peer-reviewed scientific paper with level
2 evidence [5], one large cohort study [15] and one open
prospective international multi-center study [16].
Neurosurgery for psychiatric disorders is a sensitive topic
in many parts of the world. For that reason, but also for
clinical and ethical reasons, it is only logical that the
requirements are set high for it to become “standard of
care”. On the other hand, it would be unreasonable and
imprudent to continue to view this approach as purely
investigational once sufficient evidence of safety and effi-
cacy are demonstrated to validate the intervention as a
treatment.
This represents a step forward, but in order to meet the
criteria outlined above, at least one additional, well-
designed, blinded clinical trial will be necessary. Until then,
surgery can be offered for refractory OCD based on the
promising data obtained thus far, albeit with proper reg-
ulatory oversight. In the US, despite the FDA HDE approval
statement from 2009, review by an institutional review board
(IRB) remains necessary. It is our view that in whatever
jurisdiction within which a surgeon practices, it is in the
interest of patients and the integrity of the work that until
DBS in OCD is fully vetted as an established therapy, sur-
geons consult their local IRB and/or research ethics com-
mittees when undertaking investigational procedures and as
required by local jurisdictional laws and prevailing norms.
Surgery for OCD remains a treatment of last resort, and
careful patient selection according to clear definitions of
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“treatment refractoriness” is recommended [21]. Clinicians
and researchers are encouraged as much as possible to
design and conduct randomized controlled trials to further
evaluate this treatment as well as to investigate suitable
brain targets for OCD and other psychiatric indications.
The Task Force affirms that it is incumbent upon psy-
chiatrists to collaborate with surgeons and to drive this
process, as have done the many neurologists worldwide
who drove and are still driving the field of surgery for
Parkinson’s, other movement disorders and epilepsy, both
clinically and scientifically. The future of surgical treatment
of psychiatric patients remains in the realm of the
psychiatrist.
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